fda tirzepatide shortage resolved date Compounded Semaglutide & 2025: Safe Use Guide FDA confirms end of Eli

DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R

This is a rare but serious condition that requires immediate medical attention

GLP-1 receptor agonists, such as semaglutide and liraglutide, originally developed for diabetes and weight loss, are now being investigated for their potential to reduce alcohol and cocaine use

The most frequent side effects are a GI nightmare: nausea (up to half of users!), vomiting, diarrhea, constipation, abdominal pain

The more recent tests show clear improvement, which is exactly the trajectory researchers want to see

This pathway addition makes Retatrutide uniquely suited for research programs examining energy expenditure beyond appetite suppression alone